Jan 6, 2026, 13:39
JAMA Neurology: No Added Benefit of Dual Therapy After Ischemic Stroke in Case of AFib
JAMA Neurology shared on LinkedIn:
”In patients with ischemic stroke and concurrent nonvalvular atrial fibrillation and ASCVD, adding an antiplatelet agent to anticoagulant therapy offered no net clinical benefit over anticoagulant monotherapy.
Read the full article in JAMA.
Article: Optimal Antithrombotics for Ischemic Stroke and Concurrent Atrial Fibrillation and Atherosclerosis. A Randomized Clinical Trial
Authors: Shuhei Okazaki, Kanta Tanaka, Yukako Yazawa et al.
Stay updated on all scientific advances with Hemostasis Today.
-
May 25, 2026, 05:25Abdullah Mohsin: Automated Detection of DVT Using Deep Learning and Doppler Ultrasound
-
May 25, 2026, 05:07The Dual Role of PAI-1 Mutations in Bleeding and Thrombotic Disorders – ICHCC
-
May 25, 2026, 05:04Fibrinogen αC Domain Lysines Drive Plasminogen Binding and Plasmin Generation – JTH
-
May 25, 2026, 04:50Gülşah Türkoğlu: An Encouraging Momentum Around the Adoption of Resolutions on Stroke Care at WHA79
-
May 25, 2026, 04:47Krishnakant Prasad: A Quick Clinical Review of Renal Papillary Necrosis
-
May 25, 2026, 04:40Rajiv Kumar Jain: World Health Assembly Adopts First-Ever Global Resolution on Stroke Prevention and Care
-
May 25, 2026, 04:23Sarfraz Ahmad: Diagnostic and Therapeutic Challenges in ICA Aneurysm Presenting With Epistaxis
-
May 24, 2026, 17:48Flora Peyvandi: Crucial Role of Placental ADAMTS13 in Perinatal Survival
-
May 24, 2026, 17:13Mahtab Mashayekhi: The Evolving Role of Red Blood Cell Exchange in the Management of SCD